BerGenBio ASA (LTS:0RU5)
kr 9.9 0 (0%) Market Cap: 388.17 Mil Enterprise Value: 213.33 Mil PE Ratio: 0 PB Ratio: 2.62 GF Score: 54/100

Q2 2020 Bergenbio ASA Earnings Call Transcript

Aug 18, 2020 / 08:00AM GMT
Release Date Price: kr1817.9
Richard Godfrey
BerGenBio ASA - CEO

Hello. Good morning. Welcome to BerGenBio's quarter 2 half year report highlight 2020. My name is Richard Godfrey, I'm the CEO of BerGenBio. And I'm joined by Rune Skeie, our CFO; Hani Gabra, our Chief Medical Officer; and James Lorens, our Chief Scientific Officer.

I'd like to give a special welcome to our new shareholders. We have more than 10,000 shareholders in the company now, and I'd also like to extend a special welcome to new international shareholders that have recently joined our register.

Next slide, please. We are, of course, a public company, and I should draw your attention to these forward-looking statements and ask that you pay attention to the details.

Next slide, please, Slide 3. By way of a corporate overview and introduction, BerGenBio is a world leader in understanding the role and function of AXL biology. AXL is a tyrosine kinase that drives aggressive disease including immune-evasion, therapy-resistant and metastatic cancer, fibrosis and also viral infections. BerGenBio has a number of inhibitors of AXL in clinical

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot